GlycoMark (1,5-AG) At-Home and Finger-Prick Options: Normal Range, Optimal Targets, and What the Test Reveals

Two entities to keep straight

"1,5-AG" (1,5-anhydroglucitol) is the analyte. "GlycoMark" is the commercial brand name most U.S. reference laboratories use for the assay. It is not a glucose meter, not a continuous glucose monitor (CGM), and not the same thing as fructosamine, even though all three sometimes get grouped together as "short-term glycemic markers." This article is about the 1,5-AG/GlycoMark test specifically.

The direct answer

There is currently no FDA-cleared at-home or finger-prick version of the 1,5-AG/GlycoMark test sold in the United States. The assay is run on serum or plasma from a standard venous blood draw and processed on a laboratory immunoassay platform; a capillary finger-prick format faces both a stability problem (1,5-AG is less stable in whole capillary blood than in processed serum) and a sensitivity problem (the analyte circulates in a low microgram-per-milliliter range that is difficult for lateral-flow point-of-care sensors to resolve reliably). If your goal is real-time, at-home postprandial glucose data today, a CGM is the closest practical substitute, though it measures a different thing (glucose itself, continuously) rather than the cumulative 1,5-AG summary.

How 1,5-AG works, in plain terms

1,5-AG is a glucose-like sugar alcohol present in most foods. Under normal conditions the kidney reabsorbs nearly all of the 1,5-AG that gets filtered. When blood glucose rises above the renal threshold, roughly 180 mg/dL, glucose competes with 1,5-AG for the same renal transporter (SGLT-2), and more 1,5-AG spills into urine. Serum 1,5-AG then falls. Because that competition depends on how often and how high glucose spikes, and because 1,5-AG's own body pool turns over on the order of one to two weeks, a low result implies frequent or severe glucose excursions above the renal threshold in the recent past. A high result implies the opposite: glucose has rarely, if ever, exceeded that threshold recently.

This is the core mechanism that makes 1,5-AG useful in a specific gap: HbA1c averages glucose over about 90 days and is diluted by that long window, so it can look reassuring even in someone who spikes sharply after most meals. 1,5-AG is sensitive to exactly that pattern because its window is short. The two markers answer different questions and are complementary rather than interchangeable.

Reference range versus a proposed "optimal" target

These are two different numbers, and mixing them up is a common source of confusion.

Reference range. Commercial U.S. laboratories report a "normal" (non-diabetic) reference interval that is commonly cited around 10.7 to 32.0 mcg/mL, with interpretive tiers roughly along these lines:

These bands originate from the assay's FDA clearance materials and manufacturer product literature. The general fact of FDA clearance and the existence of interpretive cutoffs can be checked against the FDA's own premarket notification database (FDA 510(k) database); the precise numeric boundaries should be confirmed against the current product insert for the specific lab running your sample, because reference intervals can vary slightly between laboratories and platforms.

Proposed optimal target. Some metabolic-medicine and longevity-oriented clinicians treat the bottom of the standard reference range as still representing a person who spikes often, and instead use a higher working target, above roughly 19 mcg/mL, as a marker of "postprandial glucose rarely exceeds 180 mg/dL." This is a clinical practice pattern and an extrapolation from population cohort data linking lower 1,5-AG to higher long-term cardiometabolic risk, not a value endorsed as a formal treatment target by a diabetes guideline body. Cohorts such as the Atherosclerosis Risk in Communities (ARIC) study have reported that people in the lowest quartile of 1,5-AG carry higher long-term cardiovascular risk than those with higher levels, but the exact magnitude of that association (relative risk, hazard ratio, or percentage increase) should be verified against the primary publication before being repeated as a precise number; the specific effect-size figures in earlier drafts of this material could not be confirmed against a verified source and have been removed rather than restated.

Is there an at-home or finger-prick version?

No, not one cleared for U.S. sale as of 2025. Some non-U.S. manufacturers have described dry-chemistry, whole-blood analyzers intended for capillary 1,5-AG measurement, but none of these has FDA 510(k) clearance for U.S. sale, and any comparative accuracy figures for such devices need direct verification against the primary validation literature before being treated as reliable.

Two practical U.S. pathways exist for getting the standard venous-draw version:

1. Physician or telehealth order. A licensed clinician orders CPT 82985 through a major reference laboratory. You go to any standard phlebotomy draw site. Results typically return within about a week, though exact turnaround varies by lab.
2. Direct-access lab ordering. Several direct-to-consumer lab-ordering services allow patients to order 1,5-AG/GlycoMark without a prescription in most states, routing the sample to a standard reference lab. Cash-pay pricing changes over time and by vendor; check current pricing directly with the ordering service rather than relying on a fixed figure, since price data go stale quickly.

CGM as a functional, at-home proxy. A continuous glucose monitor does not measure 1,5-AG, but it measures the underlying event that drives 1,5-AG down: time spent above a given glucose threshold. Using a CGM for one to two weeks and reviewing "time above range" is the closest at-home approximation of what a single 1,5-AG draw summarizes retrospectively. The two are complementary rather than redundant: a CGM trial shows which specific meals or patterns cause spikes; a 1,5-AG value quantifies the cumulative burden of those spikes as one number.

The one exception that changes everything: SGLT-2 inhibitors

This is the most consequential fact on this page. SGLT-2 inhibitors (empagliflozin, dapagliflozin, canagliflozin, and other drugs in the class) work by blocking the same renal transporter that 1,5-AG competes for during reabsorption. That means these drugs artificially suppress 1,5-AG regardless of how well glucose is actually controlled. A patient on an SGLT-2 inhibitor with excellent glycemic control can still show a very low 1,5-AG, and a clinician unaware of this interaction could misread it as evidence of poor control. Anyone taking an SGLT-2 inhibitor should not rely on 1,5-AG as a glycemic marker; CGM data or fructosamine are more appropriate alternatives in that setting. This interaction is broadly acknowledged in diabetes clinical practice and FDA labeling for the SGLT-2 class; if a specific published source is needed for a chart note, confirm the current product labeling for the individual SGLT-2 drug in question rather than relying on a secondary summary.

Who this test is actually useful for

• People with a near-normal HbA1c who have symptoms suggestive of postprandial swings, post-meal fatigue, reactive-hypoglycemia-type symptoms two to three hours after eating, or unexplained weight gain despite an unremarkable A1c. The American Diabetes Association's Standards of Care acknowledges that postprandial glucose patterns carry information beyond HbA1c in some patients, which is the general clinical rationale for adding a short-window marker like 1,5-AG in this gray zone.
• People starting or titrating a therapy expected to change postprandial glucose, such as a GLP-1 receptor agonist, where 1,5-AG could plausibly track improvement in postprandial control faster than HbA1c does, since HbA1c takes weeks to reflect a change. Specific magnitude claims about how much 1,5-AG rises with a given drug and dose require confirmation against the primary trial literature before being used clinically; they are not restated here as fixed numbers.
• People with reduced kidney function or advanced liver disease should generally not rely on 1,5-AG. Reduced glomerular filtration lowers the filtered load of both glucose and 1,5-AG, which can artificially raise 1,5-AG even when glucose control is actually poor. Guideline bodies addressing diabetes biomarker selection in chronic kidney disease, including the National Kidney Foundation's clinical practice guidance, generally support using an alternative marker (fructosamine or CGM data) in more advanced CKD rather than 1,5-AG.
• Pregnancy is an area of active research interest for 1,5-AG as an early gestational diabetes risk marker, but plasma volume expansion and altered renal thresholds during pregnancy can shift baseline values, and 1,5-AG is not currently part of routine ACOG prenatal screening. Any specific risk-ratio figure from pregnancy cohort studies should be checked against the original publication before being used to counsel a patient, since exact numbers could not be independently confirmed for this draft.

What the evidence does and does not establish

Established: 1,5-AG falls when glucose repeatedly exceeds roughly the renal threshold, and it reflects a much shorter time window than HbA1c. SGLT-2 inhibitors invalidate the test by acting on the same renal transporter. No FDA-cleared at-home or finger-prick 1,5-AG test exists in the U.S. as of 2025.

Plausible but not settled as a treatment target: Using a value above roughly 19 mcg/mL as an "optimal" cardiometabolic target, rather than simply staying inside the standard reference range, is a clinical practice pattern built on observational cohort associations between low 1,5-AG and downstream cardiovascular risk. It has not been adopted as a formal treatment threshold by a major diabetes guideline body, and using it to drive medication decisions (for example, starting a GLP-1 agonist based on 1,5-AG alone) goes beyond what the evidence in this space currently supports on its own.

Not established from the material reviewed here: Precise numeric effect sizes (percentage risk increases, exact correlation coefficients, specific mcg/mL changes with a named drug at a named dose) that appeared in earlier versions of guidance on this topic could not be verified against a confirmed primary source during this review and have been removed rather than repeated. Anyone using this page to write a clinical claim with a specific number should trace it back to the original trial or cohort publication first.

A decision framework for interpreting a 1,5-AG result

Glycomark results should not replace a clinician's individual assessment. Rather, they provide a framework for discussing short-term glycemic patterns with patients after results are available.

Step 1, Check the disqualifiers first.

• On an SGLT-2 inhibitor? The result is not interpretable as a glycemic marker. Stop here; use CGM or fructosamine instead.
• eGFR below roughly 45 mL/min/1.73 m², or advanced liver disease? Treat the result with caution; consider an alternative marker.
• Recent prolonged fasting (more than ~48 hours) or a very low-carbohydrate diet before the draw? A mild reduction in 1,5-AG from reduced dietary intake, rather than from glucose spikes, is possible; note the context.

Step 2, If none of the above apply, weigh the result against HbA1c and symptoms.

Step 3, Decide what changes because of the result, not just what the number is. A test that does not change a management decision (diet trial, CGM referral, medication reconsideration, or further workup) has limited value in isolation. If a clinician cannot articulate what they would do differently based on a high versus a low 1,5-AG in a specific patient, the test may not be the right next step for that patient.

Practical logistics

The test is ordered under CPT code 82985, generally through a physician, telehealth clinician, or a direct-access lab-ordering service, and requires a standard venous blood draw rather than fasting beyond what is typical for a routine metabolic panel. Insurance coverage varies by payer and by the diagnosis code used; confirm coverage with your insurer before ordering, since coverage policy and cash-pay pricing both change over time and are not repeated here as fixed figures.

If you use a CGM already, 1,5-AG can still add value: the CGM shows which meals cause spikes in real time, while a 1,5-AG value gives a single retrospective summary of how much total excursion burden occurred over the prior one to two weeks. Neither replaces the other.